Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

By T. Powles, I. Durán, M. S. van der Heijden, Y. Loriot, N. Vogelzang, U. de Giorgi, S. Oudard, M. Retz, D. Castellano, A. Bamias and 14 more. The Lancet, 2018

1,232 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/b37a983402c1f0c82c2b31f119af6fbad394bfb2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Timothy A. Chan
2. Sergio A. Quezada
3. M. Hellmann
4. A. Schoenfeld

Citations in the corpus

• Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “We have attempted to infer the rates of acquired resistance based upon available duration of response data among different tumor types (Antonia et al., 2019; Armand et al., 2018; Balar et al., 2018; Burtness et al., 2019; Chen et al., 2019a; Cohen et al., 2019; Fehrenbacher et al., 2018; Fradet et a”
• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “PD-L1 expression by IHC is an FDA-approved companion diagnostic test for pembrolizumab in NSCLC, gastric / gastroesophageal junction adenocarcinoma, cervical cancer and UC [15-20], and has shown some predictive ability across several other cancer types including head and neck and small cell lung car”